Rheumatoid Arthritis and Sjogren's Disease: Rapcabtagene Autoleucel Study

We are evaluating the safety of a new treatment for people with difficult-to-treat rheumatoid arthritis and severe Sjogren's disease. The study also looks at how the treatment works in the body.

Safety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesInjectionInternal MedicineRheumatology

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Cyclophosphamide
Cyclophosphamide is a cancer-fighting and immune-suppressing substance used to treat various cancers and some severe autoimmune conditions.
Fludarabine Phosphate
Fludarabine phosphate is used to treat certain blood cancers, especially chronic lymphocytic leukemia and some lymphomas.
Tocilizumab
Tocilizumab is a substance that reduces harmful inflammation by targeting the immune system to treat autoimmune conditions such as rheumatoid arthritis.

What experimental substances are being tested?

Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.

Ytb323
Rapcabtagene Autoleucel

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...
Centre Hospitalier Universitaire De Bordeaux
1005:Rhumatologie
Bordeaux, France
Centre Hospitalier Universitaire De Bordeaux
1005:Rhumatologie
Bordeaux, France
Centre Hospitalier Universitaire De Bordeaux
1005:Rhumatologie
Canéjan, France
Sponsor: Novartis Pharma AG
Last updated: Nov 27, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.